MLLT10抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: K562 cell lysate, Primary antibody: P07791(MLLT10 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

The MLLT10 antibody targets the MLLT10 protein, encoded by the *MLLT10* gene (Mixed-Lineage Leukemia Translocated to 10), also known as *AF10*. This gene is frequently involved in chromosomal translocations associated with acute leukemias, particularly acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). MLLT10 functions as a transcriptional regulator, interacting with chromatin-modifying complexes such as the DOT1L histone methyltransferase complex. It plays a role in histone H3 lysine 79 methylation (H3K79me), influencing gene expression, chromatin dynamics, and cellular differentiation. Dysregulation of MLLT10. often through fusion proteins (e.g., CALM-AF10 or PICALM-MLLT10), disrupts epigenetic regulation, leading to aberrant proliferation and leukemogenesis.

MLLT10 antibodies are essential tools in cancer research, enabling detection of MLLT10 expression, localization, and fusion protein products via techniques like Western blot, immunofluorescence, and immunohistochemistry. They are crucial for studying MLLT10's role in leukemia pathogenesis, evaluating its interaction partners, and exploring therapeutic strategies targeting associated pathways (e.g., DOT1L inhibitors). Additionally, these antibodies aid in diagnosing translocation-positive leukemias and understanding broader mechanisms of epigenetic dysregulation in cancer. Research using MLLT10 antibodies continues to uncover its contributions to oncogenic transcriptional programs and potential as a biomarker or therapeutic target.